COVID-19 therapy (oncogenuity)

N/A

Report date: 2023/12/26 16:12:46
NME

Base Information

Drug NameCOVID-19 therapy (oncogenuity)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncogenuity Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncogenuity Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A